Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Review and clinical perspectives for the use of infliximab in ulcerative colitis Panaccione R; Fedorak RN; Aumais G; Bernard EJ; Bernstein CN; Bitton A; Croitoru K; Dieleman LA; Enns R; Feagan BG; Franchimont D; Greenberg GR; Griffiths AM; Marshall JK; Pare P; Patel S; Penner R; Render C; Seidman E; Steinhart AHCan J Gastroenterol 2008[Mar]; 22 (3): 261-72Infliximab is a chimeric, monoclonal anti-tumour necrosis factor-alpha antibody. It has been previously demonstrated to be an effective treatment for patients with Crohn's disease who do not achieve the desired response with conventional treatments. Although the etiology of ulcerative colitis (UC) differs from that of Crohn's disease, randomized controlled trials have demonstrated that infliximab is also beneficial for the treatment of moderate to severe UC in patients who are either intolerant of or refractory to immunosuppressant agents or steroids, or those who are steroid-dependent. A review of the literature is followed by practical recommendations regarding infliximab that address the needs of clinicians and UC patients. Where there is a lack of evidence-based information, the expert panel provides its combined opinion derived from the members' clinical experiences.|Anti-Inflammatory Agents/administration & dosage/*therapeutic use[MESH]|Antibodies, Monoclonal/administration & dosage/*therapeutic use[MESH]|Colitis, Ulcerative/*drug therapy[MESH]|Contraindications[MESH]|Gastrointestinal Agents/administration & dosage/*therapeutic use[MESH]|Humans[MESH]|Infliximab[MESH]|Infusions, Intravenous[MESH]|Randomized Controlled Trials as Topic[MESH]|Remission Induction[MESH]|Risk Assessment[MESH] |